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Lia E. Bang, MD,† Henning Bundgaard, MD, DMSC,† Lars B. Nielsen, MD, DMSC,‡
Jørn W. Helge, PHD,* Flemming Dela, MD, DMSC*
Copenhagen, Denmark
Objectives Glucose tolerance and skeletal muscle coenzyme Q10 (Q10) content, mitochondrial density, and mitochondrial
oxidative phosphorylation (OXPHOS) capacity were measured in simvastatin-treated patients (n  10) and in
well-matched control subjects (n  9).
Background A prevalent side effect of statin therapy is muscle pain, and yet the basic mechanism behind it remains un-
known. We hypothesize that a statin-induced reduction in muscle Q10 may attenuate mitochondrial OXPHOS ca-
pacity, which may be an underlying mechanism.
Methods Plasma glucose and insulin concentrations were measured during an oral glucose tolerance test. Mitochondrial
OXPHOS capacity was measured in permeabilized muscle fibers by high-resolution respirometry in a cross-
sectional design. Mitochondrial content (estimated by citrate synthase [CS] activity, cardiolipin content, and
voltage-dependent anion channel [VDAC] content) as well as Q10 content was determined.
Results Simvastatin-treated patients had an impaired glucose tolerance and displayed a decreased insulin sensitivity
index. Regarding mitochondrial studies, Q10 content was reduced (p  0.05), whereas mitochondrial content
was similar between the groups. OXPHOS capacity was comparable between groups when complex I– and
complex II–linked substrates were used alone, but when complex I  II–linked substrates were used (eliciting
convergent electron input into the Q intersection [maximal ex vivo OXPHOS capacity]), a decreased (p  0.01)
capacity was observed in the patients compared with the control subjects.
Conclusions These simvastatin-treated patients were glucose intolerant. A decreased Q10 content was accompanied by a de-
creased maximal OXPHOS capacity in the simvastatin-treated patients. It is plausible that this finding partly ex-
plains the muscle pain and exercise intolerance that many patients experience with their statin treatment.
(J Am Coll Cardiol 2013;61:44–53) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.036Statins (3-hydroxy-3-methyl-glutaryl coenzyme A reduc-
tase [HMG-Co A reductase] inhibitors) are widely used in the
treatment of hypercholesterolemia (1). Hypercholestero-
lemia is a major risk factor for development of stroke and
coronary heart disease (1,2). Statins are reported to have
beneficial effects (reduces the production of reactive oxygen
species [ROS] and increases antioxidant capacity) on heart
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2012, accepted September 25, 2012.muscle, whereas the opposite is observed in skeletal muscle
from human subjects (3). Adverse effects of statin treatment
on skeletal muscle (from myositis to rhabdomyolysis) have
been reported, but the mechanism behind these myopathic
changes is not fully understood (4). Muscle pain is a less
severe side effect of statin treatment, but it is still quite
discomforting for the patients, and the prevalence ranges
from 10% in patients who are sedentary to 75% in athletes
(5). The incidence of myopathy reported in randomized
controlled trials is much lower than 10% (6); a part of the
reason for this discrepancy is the definition of myopathy. In
many randomized controlled trials, the definition of myop-
athy is an increased creatine kinase (CK) concentration of
more than 10 times the normal range (7). It has been
reported that myopathy (biopsy confirmed) can occur with-
out elevation in CK levels (8). In observational studies, it
has been reported that around 10% of patients receiving
statins develop myopathy (9,10). These muscle symptoms
are clinically of major importance for several reasons, not
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compliance of the patients. Statins act via the mevalonate
pathway to reduce the formation of cholesterol, but im-
pingement of this pathway may also affect the formation of
the mitochondrial cofactor, coenzyme Q10 (Q10) (11). In
hypercholesterolemic patients treated with simvastatin, the
content of Q10 in skeletal muscle was reduced, and this was
paralleled by a reduction in mitochondrial content (esti-
mated by citrate synthase [CS] activity and mitochondrial
DNA content), but only when a lipophilic statin was used
(simvastatin) (12,13). A lower dose of simvastatin (20
mg/day) did not produce measurable changes in skeletal
muscle Q10 content (14,15). The acute effect of statin
treatment on mitochondrial oxidative phosphorylation
(OXPHOS) capacity in human skeletal muscle has been
investigated, and a decrease in OXPHOS capacity with
complex I–linked substrates was reported, whereas respira-
tion with complex II–linked substrates was unaffected (16).
Recently, the same group investigated mitochondrial func-
tion in patients treated with different statins (lipophilic
and hydrophilic) and reported the same results: decreased
complex I OXPHOS capacity in the patients and no
differences in complex II–linked OXPHOS capacity (17).
However, the study groups were not matched for maximal
oxygen uptake (physical fitness), which is problematic be-
cause exercise training is the most powerful stimulus for
mitochondrial biogenesis (18), and differences in mitochon-
drial content (which was not measured in the study [17])
would have had a major influence on the respiratory results.
There is a paucity of studies of skeletal muscle mitochon-
drial function in hypercholesterolemic patients in long-term
treatment with statins. The present study was therefore under-
taken to test whether Q10 content, maximal OXPHOS capac-
ity, mitochondrial content, and mitochondrial substrate sensi-
tivity were affected in patients in long-term treatment with a
cholesterol-lowering drug (simvastatin).
Recently, it has been reported that statin treatment
impairs insulin sensitivity and increases the prevalence of
type 2 diabetes (19–22); and it seems that lipophilic statins
(i.e., simvastatin, atorvastatin, fluvastatin, lovastatin) have a
more pronounced effect on insulin sensitivity compared with
hydrophilic statins (i.e., pravastatin, rosuvastatin) (23). A
secondary aim of the present study was to test whether these
findings of decreased insulin sensitivity would be reflected in
a simple oral glucose tolerance test (OGTT) in patients
treated with simvastatin.
Methods
Participants. Twenty male subjects were recruited to par-
ticipate in the study: 10 patients with hypercholesterolemia,
in medical treatment with simvastatin (10 to 40 mg/day: 10
mg/day, n  1; 20 mg/day, n  4; and 40 mg/day, n  5)
for at least 12 months (average: 5 years) (recruited via the Unit
for Inherited Cardiac Diseases, Department of Cardio-
logy, Rigshospitalet), and 10 healthy control subjects. The fgroups were matched for age,
weight, body mass index, fat per-
centage (total and abdominal),
and maximal oxygen uptake
(VO2MAX) (Table 1). The pa-
ients with hypercholesterolemia
ook 1 dose of medication per
ay in the evening and did not
ake any other medication, and
ontrol subjects did not take any
edication. Medication was not
ithdrawn prior to the test days.
ubjects with a family history of
ype 2 diabetes were excluded
rom the study. Muscle pain was
valuated with the visual analog
cale. After the subjects were re-
ruited and the blood and skele-
al muscle were analyzed, 1 of the
ontrol subjects turned out to
ave impaired glucose tolerance;
herefore, data from this subject
ere omitted, leaving 9 in the control group.
The ethics committee of the municipality of Copenhagen
nd Frederiksberg in Denmark approved the study protocol
H-4-2009-095), and oral and written consent were ob-
ained from each participant in accordance with the Hel-
inki Declaration.
xperimental protocol. Subjects reported to the laboratory
t 8:00 AM after an overnight fast (10 to 12 h) on 2 separate
ays. The subjects were instructed to abstain from alcohol
nd strenuous exercise the day before each visit. On the first
ay, a medical history was obtained, followed by a standard
-h OGTT with blood samples drawn at baseline (fasting)
nd every 30 min until 2 h for glucose and insulin measure-
ents. A resting electrocardiogram was then recorded to
xclude individuals with signs of coronary ischemia, fol-
owed by measurement of body composition using a dual-
nergy X-ray absorptiometry scan (Lunar Prodigy Advance,
unar, Madison, Wisconsin). Finally, an incremental cy-
ling test was performed to determine VO2MAX (Jaeger ER
800, Erich Jaeger, Würzburg, Germany). Achievement of
VO2MAX was accepted when a respiratory exchange ratio
1.15 and/or maximal heart rate (220  age) was present,
or a leveling off or decline in VO2 was reached. For further
characterization of fitness, the daily physical activity was
evaluated with the International Physical Activity Ques-
tionnaire (24). On day 2, subjects were placed in a supine
position; after 30 min, a blood sample was drawn, and a
muscle biopsy was obtained from the m. vastus lateralis.
Analytical procedures. MUSCLE BIOPSIES. The muscle bi-
psies were divided into 3 parts; the first part was quickly
rozen in liquid nitrogen within 15 s after sampling; the
econd part was mounted in a mounting medium (Tissue-
ek, Hounisen Laboratorieudstyr, Risskov, Denmark) and
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
C50  substrate sensitivity
CK  creatine kinase
CS  citrate synthase
HAD  beta-hydroxyacyl-
CoA dehydrogenase
OGTT  oral glucose
tolerance test
OXPHOS  oxidative
phosphorylation
Q10  coenzyme Q10
ROS  reactive oxygen
species
VDAC  voltage-dependent
anion channel
VO2MAX  maximal oxygen
uptakerozen in isopentane cooled by liquid nitrogen; the third
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Mitochondrial Function and Statin Treatment January 8, 2013:44–53part was placed in a relaxing buffer (BIOPS) and immedi-
ately analyzed for mitochondrial respiration. The first and
second parts of the muscle biopsy were stored at 80°C
until further analysis.
ENZYME ACTIVITIES. CS and beta-hydroxyacyl-CoA dehy-
rogenase (HAD) activities were measured as previously
escribed (25).
PROTEIN CONTENT (WESTERN BLOTS). Approximately 25
mg of muscle tissue was homogenized in a buffer. From
each sample, 20 to 30 g of total protein were separated by
DS-PAGE on 12.5% Criterion gels (BioRad Laboratories,
ercules, California) and electrophoretically transferred to
olyvinylidene difluoride membranes. The following pri-
ary antibodies were used against the following proteins:
atalase (AF3398, R&D Systems, Minneapolis, Minne-
ota), coenzyme Q10 (ab41997, Abcam, Cambridge, United
ingdom), complexes I–V (MS601, MitoSciences, Eugene,
regon), glutathione peroxidase 1 (3286, Cell Signaling
echnology, Danvers, Massachusetts), beta-hydroxyacyl-
oA dehydrogenase (HADHA) (ab54477, Abcam), mito-
hondrial superoxide dismutase (MnSOD) (06-984, Milli-
ore, Billerica, Massachusetts), uncoupling protein 3
UCP3) (ab3477, Abcam), and VDAC (4661, Cell Signal-
ng Technology). Control and statin-treated subjects
ere loaded in an alternating pattern to avoid regional
Subject CharacteristicsTable 1 Subject Characteristics
Patients
(n  10)
Controls
(n  9)
Age, yrs 45 6 45 4
Treatment time, yrs 5 5 —
Weight, kg 89 [86–101] 85 [82–102]
BMI, kg/m2 27 2 27 2
Body fat, % 28 5 27 5
LBM, kg 63 8 63 6
Systolic BP, mm Hg 141 13* 121 10
Diastolic BP, mm Hg 86 11 77 6
VO2MAX, ml O2/min/kg 38 3 40 6
HRMAX, bpm 168 9 164 10
VAS, AU 2 2* 0 0
IPAQ, kcal/week 3,455 2,017 3,128 2,128
HbA1c, % 5.7 0.2* 5.2 0.2
NEFA, mol/l 455 186 412 317
TG, mmol/l 1.4 0.6 1.3 0.7
Cholesterol, mmol/l 4.8 1.0 4.3 0.7
LDL, mmol/l 3.1 1.0 2.7 0.6
HDL, mmol/l 1.3 0.3 1.2 0.3
CK, U/l 180 [145–226] 176 [117–239]
Lactate, mmol/l 0.83 [0.72–1.03] 0.96 [0.81–1.16]
SI (mg · l2)/(mmol · Mu · min) 33 [29–40]* 56 [44–92]
Values are mean  SD or median [interquartile range]. *p  0.05 for patients versus control
ubjects.
AU  arbitrary units; BP  blood pressure; BPM  beats per min; CK  creatine kinase; HbA1c 
glycated hemoglobin; HDL  high-density lipoprotein; HR  heart rate; IPAQ  International Physical
ctivity Questionnaire; LBM  lean body mass; LDL  low-density lipoprotein; NEFA  nonesterified
fatty acids; SI peripheral insulin sensitivity (Cederholm index); TG triglycerides; VAS visual analog
scale; VO2MAX maximal oxygen uptake.ariation in transfer efficiency. Protein expression in (imvastatin-treated subjects was measured relative to the
ean values of the control group; all analyses were
erformed twice.
MYOSIN HEAVY CHAIN ANALYSIS. Analysis of myosin heavy
chain composition has been described in detail elsewhere (26).
QUANTIFICATION OF SKELETAL MUSCLE LIPIDS (CARDIOLIPIN
AND CHOLESTEROL). Lipids were extracted from approxi-
mately 20 mg (wet weight) of muscle with chloroform/
methanol (27) and redissolved in toluol (1 l/mg wet weight)
for quantitative thin layer chromatography (28). The preci-
sion and accuracy of this assay have been reported elsewhere
(27,29).
MITOCHONDRIAL RESPIRATION. Mitochondrial respiratory
apacity was measured in permeabilized skeletal muscle
bers. The details of the procedure have been described
reviously (30). Briefly, all respiratory measurements were
arried out in duplicate after hyperoxygenation to avoid any
otential oxygen limitation to respiration. Five different
ubstrate and inhibitor protocols were employed simul-
aneously (Oxygraph-2k, Oroboros Instruments, Inns-
ruck, Austria).
Protocol 1 (evaluating complex I and complex II OX-
HOS capacity): State 2 respiration was assessed with
alate (2 mmol/l), glutamate (10 mmol/l), and pyruvate (5
mol/l), followed by state 3 respiration (5 mmol/l, adeno-
ine diphosphate [ADP]). Rotenone (0.5 mol/l) was
added to inhibit complex I, followed by succinate (10
mmol/l) as a substrate for complex II, then cytochrome c
(10 mol/l) was added to control for outer mitochondrial
embrane integrity. Malonate (5 mmol/l) was used to
nhibit complex II, and finally, antimycin A (2.5 mol/l)
was added to inhibit complex III.
Protocol 2 (evaluating complex I and complex I  II
OXPHOS capacity): State 2 respiration was assessed with
malate (2 mmol/l), glutamate (10 mmol/l), and pyruvate (5
mmol/l), followed by state 3 respiration (5 mmol/l, ADP).
Simultaneous electron input into complex I  II (maximal
OXPHOS capacity) was assessed with succinate (10 mmol/l),
followed by cytochrome c (10 mol/l). Finally, oligomycin
(2 g/ml) was added to inhibit complex V.
Protocol 3 (evaluating complex IV OXPHOS capacity):
Complex IV (cytochrome c oxidase) activity was measured
as follows: ADP (5 mmol/l) was added followed by cyto-
chrome c (10 mol/l) and antimycin A (2.5 mol/l)
nhibiting complex III, finally ascorbate and N,N,N=,N=-
etramethyl-p-phenylenediamine (TMPD) was added (2
mol/l and 0.5 mmol/l, respectively).
Protocol 4 (evaluating complex I substrate sensitivity):
tate 2 respiration was assessed with malate (2 mmol/l),
ollowed by state 3 respiration (5 mmol/l, ADP). Subse-
uently, glutamate (complex I linked substrate) was titrated
n 11 steps (0.1 to 96.0 mmol/l), followed by cytochrome c
10 mol/l).
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State 2 respiration was assessed with malate (2 mmol/l)
followed by state 3 respiration (5 mmol/l, ADP). Glutamate
(10 mmol/l) (complex I substrate) was added, and succinate
(complex II linked substrate) was titrated in 10 steps (0.1 to
48.0 mmol/l), followed by cytochrome c ((10 mol/l). See
Figure 1 for an overview of the used substrates and inhib-
itors in relation to the mitochondrial electron transport
chain.
Blood samples. Blood samples were collected in chilled
tubes and immediately centrifuged (2,500 g; 4°C) for 10
min. Plasma was stored at20°C or80°C before analysis.
The analysis of plasma glucose, insulin, nonesterified fatty
acids, cholesterol, low-density lipoproteins, high-density
lipoproteins, and glycated hemoglobin (HbA1c) was done as
reviously described (31). Glucose and insulin concentra-
ions during the OGTT were used to calculate the Ceder-
olm index of peripheral insulin sensitivity (32), which has
een validated against the hyperinsulinemic–euglycemic
lamp (33). Lactate and CK levels were analyzed enzymat-
cally on an automated clinical chemical analyzer (COBAS
01, Roche, Mannheim, Germany).
tatistics and calculations. Data are presented as mean 
SD in the text and in the tables, and presented in all figures
as mean  SE. p  0.05 was considered significant.
tatistical analysis of differences in mitochondrial OXPHOS
apacity between the groups was carried out with a 2-way
nalysis of variance for repeated measures. The restrictive
ssumptions, normality and equal variance, were checked
Figure 1 Simplified View of the Electron Transport Chain Illustr
Reactive oxygen species–producing complexes are emphasized. Below each comp
diphosphate; Asc  ascorbate; ATP  adenosine triphosphate; Pi  phosphate; Qefore the statistical analysis was conducted. Significant dain effects or interactions were further analyzed by the
olm-Sidak post hoc test. If normality and equal variance test
ailed, the data were transformed and reanalyzed; this has been
tated in the figure legend if this was the case. Differences
etween the 2 groups were evaluated using a 1-way analysis of
ariance. If normality of the data was not present, the data were
nalyzed using a nonparametric test, and further analyzed by
he Dunn, Tukey, or Kruskal-Wallis test. In this situation, data
re summarized with medians and quartiles (median [inter-
uartile range]) (Tables 1 and 2, and in the Results section).
earson=s correlation analysis was performed to establish the
resence of correlations. All statistical analysis was performed
sing the software program SigmaStat 3.1 (Systat Software,
an Jose, California).
The calculation of substrate sensitivity (C50) and OXPHOS
apacity has been described previously (31).
esults
asting plasma glucose and insulin concentrations were
omparable between groups (Fig. 2). During the OGTT,
lucose concentration was significantly higher (p  0.05) in
atients compared with controls, resulting in an increased
p  0.05) area under the glucose curve in the simvastatin-
reated patients (Fig. 2). During the OGTT, insulin levels
ere similar between groups. Patients had impaired insulin
ensitivity (p  0.05) (Cederholm Index) compared with
ontrols (Table 1). Four of the 10 patients reported muscle
ain, whereas none of the controls did (Table 1). No
the Electron Carrier Function of Q10
listed the substrates and inhibitors that were used. ADP  adenosine
coenzyme Q10; TMPD  N,N,N=,N=-tetramethyl-p-phenylenediamine.ating
lex is
ifference was found in plasma lactate between the 2 groups.
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controls (180 [145 to 226] U/l vs. 176 [117 to 239] U/l,
respectively) (Table 1). Characteristics and blood data of the
patients and control subjects are provided in Table 1 and
Figure 2.
Muscle characteristics. Q10 protein content was reduced
(p  0.05) in patients compared with control subjects
(Table 2). The antioxidant (catalase [p  0.05], MnSOD
[p  0.01], and glutathione peroxidase [p  0.05]) as well
as UCP3 (p  0.01) protein content was significantly reduced
in patients compared with control subjects (Table 2). Complex
IV content was significantly reduced (p  0.05), whereas
complex V showed a tendency (p  0.07) to be reduced in
patients compared with control subjects, but complex I to
III protein content was similar between the groups (Table 2). CS
activity, VDAC protein content, and cardiolipin content
were similar between groups. When VDAC protein content
was expressed per CS activity (VDAC/CS activity) or
cardiolipin content (VDAC/cardiolipin content), patients
had a significantly (p  0.05) higher ratio compared with
control subjects (data not shown); this could indicate that
VDAC protein content is increased due to simvastatin
treatment. A tendency (p  0.06) towards lower HAD
Skeletal Muscle AnalysisTable 2 Skeletal Muscle Analysis
Patients
(n  10)
Controls
(n  9)
Protein content
Coenzyme Q10, AU 0.84 0.15* 1.00 0.18
Catalase, AU 0.58 0.33* 1.00 0.51
MnSOD, AU 0.74 0.20* 1.00 0.18
Glutathione peroxidase, AU 0.40 0.21* 1.00 0.81
UCP3, AU 0.20 [0.11–0.45]* 1.04 [0.64–1.46]
HAD, AU 0.83 0.19 1.00 0.19
VDAC, AU 1.19 0.39 1.00 0.26
Complex I, AU 0.81 0.24 1.00 0.31
Complex II, AU 0.84 0.15 1.00 0.19
Complex III, AU 1.00 0.22 1.00 0.20
Complex IV, AU 0.81 0.19* 1.00 0.18
Complex V, AU 0.82 [0.77–0.96] 0.98 [0.89–1.13]
Enzyme activities
CS activity, mol/g dw/min 101 18 116 25
HAD activity, mol/g dw/min 89 16 109 27
Skeletal muscle lipids
Cardiolipin, g/mg ww 0.49 0.08 0.55 0.10
Free cholesterol, nmol/mg ww 0.96 0.15 1.05 0.16
Skeletal muscle fiber types
MHC I, % 42 10* 58 16
MHC IIA, % 39 10 29 12
MHC IIX, % 19 7 13 5
Values are mean  SD or median [interquartile range]. Skeletal muscle characteristics in
hypercholesterolemic patients in long-term treatment with simvastatin and in healthy control
subjects are shown. Representative Western blots are presented in Figure 6. *p 0.05 for patients
versus control subjects.
AU  arbitrary units; CS  citrate synthase; dw  dry weight; GPX  glutathione peroxidase;
HAD  beta-hydroxyacyl-CoA dehydrogenase; MHC  myosin heavy chain; MnSOD  manganese
superoxide dismutase; UCP3  uncoupling protein 3; VDAC  voltage-dependent anion channel;
ww  wet weight.activity was seen in patients compared with control subjects(Table 2); the same was seen in HAD protein content (p 
0.07) in patients compared with control subjects. Skeletal
muscle free cholesterol was similar in the 2 groups (Table 2).
Skeletal muscle fiber type composition was different be-
tween the groups (Table 2).
Mitochondrial respiration. OXPHOS capacity with com-
plex I–linked substrates was not different between control
subjects and patients treated with simvastatin (26  6
pmol/mg/s vs. 24 8 pmol/mg/s, respectively) (Figs. 3 and 4A).
However, substrate sensitivity was significantly higher
(p  0.05) in the patients compared with control subjects
when glutamate (complex I–linked substrate) was used
as substrate (Fig. 4B). Thus, C50 was lower in the patients
0.98  0.23 mmol/l) compared with the control subjects
1.37  0.51 mmol/l) (p  0.05) (Fig. 4B). A tendency
p  0.076) for a drug dose effect was seen in substrate
ensitivity when glutamate was used as substrate; the pa-
ients that were treated with 40 mg of simvastatin per day
n  5) had a higher mitochondrial substrate sensitivity
complex I–linked substrate) compared with patients treated
Figure 2 Plasma Glucose and Insulin Concentrations
During the 120-min OGTT
Plasma glucose (A) and insulin (B) concentrations in patients with hypercho-
lesterolemia (soild circles and soild bars) and in control subjects (open cir-
cles and open bars) are shown. Data are mean  SE. *p  0.05 for patients
versus control subjects. AUC  area under the curve; OGTT  oral glucose
tolerance test.
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the control subjects (0.84  0.06 mmol/l vs. 1.12  0.26
mmol/l vs. 1.37  0.51 mmol/l). When succinate (complex
II–linked substrate) was used as a substrate, no differences
were seen in OXPHOS capacity (Fig. 3) or in substrate
sensitivity (Fig. 5B) between the groups. However, max-
imal OXPHOS capacity with dual electron input to complex
I and II (feeding electrons into the Q intersection) was
significantly higher (p  0.01) in control subjects compared
with patients treated with simvastatin (64 10 pmol/mg/s vs.
54  8 pmol/mg/s, respectively) (Figs. 3 and 5A). When
complex I was inhibited (protocol 1, inhibition with rotenone),
no difference was seen in complex II OXPHOS capacity
(Fig. 3) between control subjects and patients treated with
simvastatin (60  9 pmol/mg/s vs. 57  15 pmol/mg/s,
respectively). No difference was seen in complex IV OXPHOS
capacity between control subjects and patients treated with
simvastatin (198  56 pmol/mg/s vs. 164  49 pmol/mg/s,
respectively) (Fig. 3). No cytochrome c response was observed
in any of the protocols (data not shown), implying that the
outer mitochondrial membrane was intact after the experimen-
tal procedure.
A weak positive correlation (r  0.46, p  0.05) was
observed between maximal OXPHOS capacity (complex
I  II–linked substrates) and Q10 content. This correlation
as not observed between OXPHOS capacity with complex
or complex II–linked substrates alone and Q10 content.
Discussion
A major and novel finding is the impaired glucose tolerance
Figure 3 Mitochondrial OXPHOS Capacity
for Complexes I, II, I  II, and IV
Oxidative phosphorylation (OXPHOS) capacity (measured as O2 flux rates per
mg tissue) in skeletal muscle from patients with hypercholesterolemia (solid
bars) and control subjects (open bars) is shown. The following substrates were
used: complex I: malate, glutamate, pyruvate, ADP; complex II: malate, gluta-
mate, pyruvate, ADP, rotenone (inhibiting complex I), succinate; complex I  II:
malate, glutamate, pyruvate, ADP, succinate; and complex IV: ADP, cytochrome
c, antimycin A, TMPD  Asc. The y-axis to the right refers to the O2 flux rates
for complex IV. Data are mean  SE. *p  0.05 for patients versus control
subjects. Abbreviations as in Figure 1.found in the patients in treatment with simvastatin, whichwas shown by a simple OGTT. Furthermore, a decrease is
found in Q10 protein content in skeletal muscle, accompa-
ied by a limitation in maximal OXPHOS capacity in the
atients treated with simvastatin. This OXPHOS limitation
as only apparent at high respiratory flux rates when the
oupled respiration was measured during experiments with
onvergent electron input from both complex I and II to the
intersection in the respiratory chain. We suggest that
hese observations may be part of the explanation of the
ost common side effects of statin treatment: muscle pain
nd weakness.
The impaired glucose tolerance found in the simvastatin-
reated patients is in agreement with previous findings of
Figure 4 Mitochondrial OXPHOS Capacity With Glutamate
(A and B) O2 flux rates per mg tissue in skeletal muscle from patients with
hypercholesterolemia (solid circles) and control subjects (open circles) are
shown for the following protocol: malate, ADP, and glutamate titration (0.1 to
96.0 mmol/l). (A) Glutamate titration where Michaelis-Menten kinetics can be
seen (entire titration protocol). (B) Extract of the respiration curve highlighting
respiration for glutamate concentration (0.1 to 2.5 mmol/l), which makes it
possible to appreciate the substrate kinetics (C50). Drop lines (B) indicate C50
(x-axis) corresponding to half maximum OXPHOS capacity (y-axis), respectively.
In order to perform the appropriate statistical testing, the data were trans-
formed before they were analyzed. Data are mean  SE. *p  0.05 for
patients versus control subjects. Abbreviations as in Figures 1 and 3.
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(19 –21), but the present study is to our knowledge the first
to demonstrate a deleterious effect on the glucose tolerance
in simvastatin-treated patients. The 3 studies by Koh et al.
(19,20,22) from 2008, 2009, and 2010 used the Quantita-
tive Insulin-Sensitivity Check Index as a surrogate measure
for insulin sensitivity, whereas the study by Ohrvall et al.
(21) from 1995 used the hyperinsulinemic–euglycemic
clamp technique. The latter study was performed in patients
with type 2 diabetes, which could be a confounding factor.
The mechanism behind this unfavorable side effect on
glucose tolerance is not known, and an explanation for the
Figure 5 Mitochondrial OXPHOS Capacity With Succinate
(A and B) O2 flux rates per mg tissue in skeletal muscle from patients with
hypercholesterolemia (solid circles) and control subjects (open circles) are
shown for the following protocol: malate, ADP, glutamate, and succinate titra-
tion (0.1 to 48.0 mmol/l). (A) Succinate titration where Michaelis-Menten
kinetics can be seen (entire titration protocol). (B) Extract of the respiration
curve highlighting respiration for succinate concentration (0.1 to 8.0 mmol/l),
which makes it possible to appreciate the substrate kinetics (C50). Drop lines
(B) indicate C50 (x-axis) corresponding to half maximum OXPHOS capacity
(y-axis). In order to perform the appropriate statistical testing, the data were
transformed before they were analyzed. Data are mean  SE. *p  0.05 for
patients versus control subjects. Abbreviations as in Figures 1 and 3.reduced glucose tolerance found in the patients can only bespeculative, but 1 clue may be that it seems as if the effect on
insulin sensitivity is more pronounced when the patients are
treated with lipophilic statins (19,22,23). Insulin-resistant
patients have been shown to have reduced UCP3 content in
the skeletal muscle (34), and in the present study, we also
found reduced UCP3 content in the simvastatin-treated
patients. UCP3 has been suggested to protect the mito-
chondria against an accumulation of nonesterified fatty acids
(35); an accumulation of these fatty acids and ceramides
and diacylglycerol in the cytosolic compartment are
linked to insulin resistance via an inhibition of the insulin
signaling cascade (36,37). Thus, the observation of glu-
cose intolerance in concert with reduced UCP3 levels
supports the view that the simvastatin-treated patients
were in a pre-insulin resistant state. Consensus about the
role of intramyocellular lipids in insulin resistance is not
reached in the literature, and further studies are clearly
needed to elucidate this.
Q10 content and mitochondrial OXPHOS capacity. Other
tudies with high simvastatin doses (80 mg/day) have
eported decreased Q10 protein content in muscle from
imvastatin-treated patients (12,13), whereas studies using
ower (20 mg/day) doses have been unable to demonstrate
ecreased muscle Q10 protein content (14,15), but no
studies have so far combined this measurement of a key
protein in the mitochondrial respiratory chain with a func-
tional (high-resolution respirometry) mitochondrial test. In
doing so, we can now show that OXPHOS capacity is not
different between patients and control subjects, when sub-
strates for complex I and complex II are used separately.
Only when complex I and II substrates were combined, thus
maximally taxing the electron transport system, did the
effect of statin treatment become apparent (Figs. 1 and 3),
Figure 6 Representative Western Blots Are Presented
The bands for the different proteins are from the same 2 subjects (a patient
and a control). GPX  glutathione peroxidase; HAD  beta-hydroxyacyl-CoA
dehydrogenase; MHC  myosin heavy chain; MnSOD  manganese superoxide
dismutase; Q10  coenzyme Q10; UCP3  uncoupling protein 3; VDAC 
voltage-dependent anion channel.
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transport system is challenged maximally. The fact that we
were able to demonstrate this impairment in OXPHOS
capacity (complex I and II substrates combined) in the
patients even at these relatively low flux rates, emphasizes
the potential of our finding (in vivo flux rates are much
higher than these ex vivo flux rates [38]). It may be
anticipated that the OXPHOS limitation observed ex vivo
in the present study serves as a mechanism for the impaired
exercise tolerance and fatigability seen in some patients
using statins. The acute effect of statins has, however, been
studied in isolated mitochondria from L6 cells (a rat skeletal
muscle cell line) (39) and in skinned human and rat muscle
(16) in which a toxic effect of simvastatin and depressed
complex I respiration was found. Recently Kwak et al. (40)
reported impaired ADP-stimulated respiration in primary
human skeletal myotubes after 48 h of simvastatin treat-
ment, and this was accompanied by increased mitochondrial
oxidative stress (hydrogen peroxide emission). It may not be
that surprising that a statin can produce an acute toxic effect
in cells, but the fact that an impairment of function can be
observed in human muscle fibers, obtained via a biopsy that
is mechanically and chemically dissected and permeabilized,
washed, and finally transferred to the respiration chamber, is
truly remarkable. It shows that the impact of long-term
treatment with the lipophilic statin simvastatin has pro-
found functional (limitation of maximal OXPHOS capac-
ity) and structural (decreased content of Q10, complex IV,
antioxidant proteins, and UCP3) impact. The present study
differs from the aforementioned studies in that the patients
are chronically treated with simvastatin, whereas the other
studies are conducted in cell lines or the skeletal muscle is
acutely treated with very high (thus not clinically relevant)
concentrations of statins. Therefore, the clinical applicabil-
ity of the present study is more obvious.
The decreased Q10 protein content in patients in
long-term treatment with simvastatin offers a mechanis-
tic explanation for the limitation in maximal OXPHOS
capacity (Figs. 1 and 3). This hypothesis requires further
testing, but is to some extent supported by the correlation
between Q10 content and maximal OXPHOS capacity,
ven though this correlation was not strong and has to be
onfirmed in other studies.
itochondrial substrate sensitivity. Skeletal muscle
rom simvastatin-treated patients had increased mito-
hondrial substrate sensitivity (lower C50 value) with
omplex I–linked substrate (glutamate) compared with
uscle from the control subjects, but no difference was
een with complex II–linked substrate (succinate). The
eason for this disparity may be explained by the difference
n muscle fiber type composition and/or mitochondrial
embrane potential. First, higher substrate sensitivity for
omplex I–linked substrates has previously been reported in
atients with type 2 diabetes compared with healthy control
ubjects (31). Second, differences between type I and type II
uscle fibers have been reported previously in rats, withype II fibers being more sensitive than type I (41).
ccordingly, the significantly lower proportion of type I
bers in the patients compared with the control subjects in
he present study may contribute to the observed difference
n substrate sensitivity between the groups. Third, it has
reviously been reported that statins, in a dose-dependent
anner, decrease the mitochondrial membrane potential
16,39). The membrane potential is mainly created by virtue
f the activity of complexes I, III, and IV, and a compro-
ised function of 1 or more of these may lower the
embrane potential. Therefore, a higher complex I sub-
trate sensitivity may be regarded as a compensatory mech-
nism for upholding the mitochondrial membrane poten-
ial. In support of this notion is our observation that the
atients treated with the highest simvastatin dose (40
g/day) also showed a nonsignificant tendency to have the
ighest substrate sensitivity compared with both patients
reated with the lowest simvastatin dose (10 to 20 mg/day)
nd the control subjects.
The difference between simvastatin-treated patients and
he control subjects in complex I–linked substrate sensitivity
s a true intrinsic event in the mitochondrion, because the
erived sensitivity parameter (C50) of the titration studies is
independent of mitochondrial density.
Muscle characteristics. In the present study, ROS produc-
tion was not measured, but other studies have shown
increased ROS production (3,42) and a decreased antioxi-
dant capacity (3) with statin treatment. The latter finding is
confirmed by the present study in which we found decreased
protein content of catalase, manganese superoxide dismu-
tase, and glutathione peroxidase. Mitochondrial content
evaluated by CS activity, cardiolipin content, or VDAC
protein content was similar between the groups (Table 2).
The ratio between VDAC and CS activity or cardiolipin
was significantly higher in the patients compared with the
control subjects, indicating that simvastatin-treated patients
have a higher abundance of VDAC content per mitochon-
drion. It has been reported that VDAC located in the outer
mitochondrial membrane is important for the in- and
outflux of Ca2 of the mitochondria (43), and the up-
egulated VDAC protein content in the simvastatin-treated
atients could be because of the known statin-induced
levation of cytoplasmic Ca2 concentration (44). In turn,
an increased Ca2 load in the mitochondrial matrix has
been linked to increased ROS production and increased
permeability transition pore opening, leading to apoptosis
(40,45). Our findings of significantly reduced antioxidant
capacity in combination with the known (3,40) elevated
ROS production in the simvastatin-treated patients make it
plausible that increased apoptosis could contribute to muscle
pain in patients treated with statins. Furthermore, we
observed a decreased protein content of complex IV in the
patients compared with the control subjects; this was a
somewhat unexpected finding.
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In summary, we found that patients treated with simvastatin
have impaired glucose tolerance compared with healthy control
subjects. Furthermore, we found that skeletal muscle from
patients treated long term with simvastatin displayed a de-
creased maximal OXPHOS capacity that may well be ex-
plained by a concomitant decrease in Q10 protein content
ithout any changes in mitochondrial content. The result is a
ompromised energetic state within the skeletal muscle, pos-
ibly explaining side effects such as myalgia and exercise
ntolerance. Finally, we have reported that simvastatin-treated
atients have an increased mitochondrial substrate sensitivity
hen complex I substrate was used, which is a true intrinsic
itochondrial event, and we hypothesize that this could be a
ompensatory mechanism for increased ROS production.
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